Inflammation, Diabetes, Ethnicity and Obesity Cohort

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Jan 12, 2017

Keywords

ClinConnect Summary

The Inflammation, Diabetes, Ethnicity and Obesity Cohort study is looking to understand how obesity, diabetes, and other health issues are connected. Obesity is a major problem in the U.S., affecting over 72 million adults and leading to serious health conditions like diabetes and heart disease. This study aims to collect information and samples from individuals in the San Francisco Bay Area to explore these connections further.

To participate, you need to be a healthy adult aged 18 to 75, which includes both men and women. People with type 2 diabetes or metabolic syndrome are welcome to join. However, there are some health conditions that would exclude you from participating, such as severe kidney disease or recent heart issues. If you join, you can expect to provide blood, stool, and tissue samples, and share information about your health. Your involvement will help researchers better understand obesity and its effects, which could lead to improved treatments and prevention strategies in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants will be healthy individuals between the ages of 18-75 years. These cutoffs are designed to allow inclusion of postmenopausal women, and younger/more active patients who are increasingly undergoing bariatric surgery.
• • Patients with either diabetes type 2 or the metabolic syndrome will be included in the cohort.
• Exclusion Criteria:
• • Participants with chronic kidney disease (\> stage 4)
• • Autoimmune/inflammatory disease (e.g., Lupus, Ulcerative Colitis, etc.)
• • Unstable angina, New York (NY) class III or IV congestive heart failure or myocardial infarction within 3 months of entry
• • Clinically significant liver disease (e.g. Cirrhosis or liver failure)
• • Weight \> 450 pounds (DXA scan weight limit)
• • History of organ transplant
• • Treatment with chemotherapy or radiation therapy at the time of enrollment in study.
• • Poorly controlled asthma (participants requiring inhaled glucocorticoids and/or oral glucocorticoids)
• • Current nasal corticosteroid use (within the past month)
• • Excessive alcohol or substance abuse
• • Current use of anabolic steroids or testosterone for bodybuilding purposes. Testosterone use is permitted if prescribed for hypogonadism and dose stable for the past 6 months.
• • Patients actively enrolled in interventional trials involving investigational agents
• • Pregnant or breast-feeding women
• • Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee.
• • History of abnormal clotting
• • Previous bariatric surgery
• • Anticoagulant use
• • Methadone medication